Gabriel Cuatrecasas works as a Family Physician since 2005 in the EAP Sarrià Primary Care Center in Barcelona and in the Diabetology and Nutrition Service group CPEN (Sagrada Familia and Quirón-Teknon Hospitals) Barcelona. His is also Associate Professor in Family Medicine at the International University of Catalonia (UIC). His main areas of interest focus on Type 2 Diabetes and Obesity management in Primary Care. He has collaborated in advisory boards, publications in diabetology, RCT and the design of type 2 Diabetes route for the Department of Health - Generalitat de Catalunya in 2021.

He is the coordinator of the Obesity Working Group at the Spanish Society of Family Medicine (SEMFYC) and at the Catalan Society of Family Medicine (CAMFIC). He is also member of the Endocrinology Group AIS-BCN Barcelona Esquerre (CatSalut – Hospital Clínic Barcelona) since 2017, redGDPS and GEDAPS group, SEEDO, SED and EASD.

Obesity is a serious, chronic and relapsing disease that stands out for its high prevalence and unfortunately suffers a clear upward trend worldwide. It generates a great impact on morbidity, mortality, quality of life and health costs. Moreover, there’s a difficulty in attending adequately obesity is partly due to a biased perception by patients and health professionals. Scientific knowledge has evolved substantially, and we began to have drugs with a real impact in terms of efficacy and safety. Because it shares many pathways with type 2 diabetes, time has come to reformulate a new understanding of both diseases.

Learning outcomes:

1. Be able to provide the bases for an adequate approach to obesity

2. Design interdisciplinary interventions in obesity

3. Know the basic therapeutic management both dietary and pharmacological

Objectives:

1. Understand why obesity is important to be considered a chronic adiposity-based disease

2. Unveil comorbidities beyond type 2 diabetes

3. Understand which subgroups are at higher risk and clinical relevance

Professor Yumuk graduated from Hacettepe University Medical School in Ankara. After completing his internal medicine residency, he became a reaserach fellow at University of Michigan School of Medicine division of endocrinology in 1993. In 1997 he completed clinical endocrinology fellowship program at University of Alabama School of Medicine. Currently he is working at Cerrahpasa Medical Faculty Endocrinology, Metabolism & Diabetes Division as a full professor.

He is a founding member and current president of Turkish Association for the Study of Obesity; is currently serving as president elect for the European Association for the Study of Obesity (EASO). He is a SCOPE Fellow, EASO-European Fellow in obesity management, and a member of the editorial board for Obesity Facts.

Dr. Yumuk is an active fellow of American College of Endocrinology and American College of Physicians. He is a member of the Focus Area Expert Panel on Diabetes, Obesity, Metabolism and Nutrition and a member of the Research Roadmap Steering Group of European Society of Endocrinology, a member of Obesity Canada CALIBRE scientific planning committee, a member of AACE Obesity Algorithm Task Force, a member of the MENA Working Group for World Obesity Federation and a member of the Policy Working Group of EASO. Dr. Yumuk’s research area is management of obesity and type 2 diabetes.

He has published numerous papers in national and international journals, and authored chapters in books in the field of endocrinology. He is also a reviewer for several journals including Obesity, Obesity Facts, Obesity Reviews, Clinical Obesity, International Journal of Obesity, Obesity Research and Clinical Practice, European Journal of Internal Medicine, and Journal of Endocrinology.

Obesity is multifactorial progressive, relapsing chronic disease. Moving further on, it is a non-communicable disease and should be treated as such. Obesity is a gateway disease to other morbidities related with cardiometabolic, mental and mechanic origins. Obesity management is not only weight loss but maintaining the lost weight by preventing weight regain in order to result in sustainable health gains. Preventing or treating obesity would prevent or treat type 2 diabetes and its complications. The algorithm for treatment of type 2 diabetes should be primarily based on obesity management by all modalities within a multidisciplinary approach. The choice of antidiabetic medications that may cause weight loss or are weight neutral are crucial.

Learning outcomes

- Understand that obesity is chronic disease similar to type 2 diabetes

- Explore the outcomes of weight loss trials

Learning objectives

- Awareness of the global syndemic of obesity and type 2 diabetes

- Position multidisciplinary obesity management in type 2 diabetes treatment algorithms